Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
Trial details
- Registry ID
- NCT05875701
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as SARS-CoV-2 rS/Matrix-M Adjuvant
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesNCT05875701 | Novavax | Phase 3 | Completed | 2023-11-11Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |